SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Andrew H who wrote (445)8/18/1997 4:09:00 AM
From: Miljenko Zuanic   of 2173
 
Andrew:

In my previous posts I stated that Pramlintide main focus is Type 1 diabetes. Definitely I was expecting little bit better results/data for this group. Will follow market reaction on news.

BTW, 0.5 % difference reduction (from placebo) on entry HbA1c ~ 8.0% is 6.25% which is significant positive results. Hope this data will be better in other trials.

mz
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News